Newsroom Archives - Page 19 of 24 - Spectral Medical Inc

Spectral Medical to Present at the Q2 Virtual Investor Summit on May 17th

TORONTO, Canada – May 11, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces Exercise of Warrants for Gross Proceeds of Approximately $3.0 Million

TORONTO, Canada – April 15, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral Medical Announces the Appointment of Chris Seto to CEO

Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial TORONTO, Canada – March 8, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced...

Spectral Medical Engages Crescendo Communications to Provide Investor Relations Services in the United States

TORONTO, CANADA — March 4, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical to Participate at the Upcoming H.C. Wainwright Global Life Sciences Conference

TORONTO, CANADA – March 2, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform...

Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use

TORONTO, Canada – February 23, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”), has been granted Investigational Device Exemption (IDE) authorization by the...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.